Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 58
Filtrar
Más filtros


Intervalo de año de publicación
2.
Indian J Dermatol Venereol Leprol ; 89(5): 710-717, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37067104

RESUMEN

Background Though diabetes mellitus (DM) is a well-recognised risk factor for onychomycosis (OM), the epidemiology of OM in diabetic patients remains largely unexplored, especially from the Indian subcontinent. Aims and objectives To estimate the prevalence of OM in diabetic patients, to identify and analyse risk factors, and correlate the severity of nail changes with glycemic control (HBA1c). Methods This cross-sectional, analytical study involved 300 diabetic patients. Patients with the clinical diagnosis of OM, supplanted by at least two of the four tests (KOH, culture, onychoscopy and nail histopathology) were considered cases of OM. Demographic and haematological profile was analysed using chi-square test/ Fischer's exact test. Logistic regression was applied to assess the independent risk factors. Results The prevalence of OM in DM patients was 34% (102/300) and significant risk factors included; age >60 years, male gender, closed shoes, disease duration >5 years, high BMI (>25) and lack of awareness about nail changes. Distal and lateral subungual OM (78%) was the commonest presentation followed by proximal subungual OM, superficial OM and total dystrophic OM. Correlation between HbA1c and the number of nails involved was found to be significant. Limitation As cases were recruited from a hospital setting, there could be chances of Berksonian bias. Conclusion The prevalence of OM in diabetic patients is high and the severity of nail changes correlates with HbA1C levels. It is important to diagnose OM early in order to treat and prevent complications.


Asunto(s)
Diabetes Mellitus , Onicomicosis , Humanos , Masculino , Persona de Mediana Edad , Onicomicosis/diagnóstico , Onicomicosis/epidemiología , Onicomicosis/tratamiento farmacológico , Estudios Transversales , Prevalencia , Centros de Atención Terciaria , Hemoglobina Glucada , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/epidemiología , India/epidemiología
3.
Indian J Dermatol Venereol Leprol ; 89(3): 408-410, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-34245540

RESUMEN

Onychomatricoma is a rare benign tumor of the nail matrix, characterized by finger-like projections that invade the nail plate. The fingernails of Caucasian women are most commonly affected. Because this tumor can easily mimic other more prevalent ungual diseases, it is crucial to be acquainted with its characteristic clinical and histopathologic features. The authors present a case of a 40-year-old man with an onychomatrichoma in the fourth left toenail, which was initially misdiagnosed and treated as onychomycosis.


Asunto(s)
Enfermedades de la Uña , Onicomicosis , Neoplasias Cutáneas , Masculino , Humanos , Femenino , Adulto , Uñas/patología , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/cirugía , Neoplasias Cutáneas/patología , Enfermedades de la Uña/diagnóstico , Enfermedades de la Uña/cirugía , Enfermedades de la Uña/patología , Onicomicosis/diagnóstico , Onicomicosis/cirugía , Onicomicosis/patología , Dedos/patología
4.
Artículo en Inglés | MEDLINE | ID: mdl-35389015

RESUMEN

Background Onychomycosis accounts for 20-40% of all nail disorders. It is difficult to cure with resistance to anti-fungal drugs, their side effects and drug interactions limiting treatment options. Itraconazole is a widely accepted oral medication used for onychomycosis while fractional CO2 laser along with a topical anti-fungal has shown promising results for nail plate clearance in onychomycosis. Aim To compare the efficacy of fractional CO2 laser with 1% terbinafine cream versus itraconazole in the management of onychomycosis. Methods A prospective, randomised, single-centre, two-arm, parallel-group interventional study was conducted at Command Hospital Air Force, Bangalore. Onychomycosis cases confirmed by KOH mount/culture-positive were included. Patients were randomly divided into two groups. Group A received 4 sessions of fractional CO2 laser every fourth week with twice-daily application of 1% terbinafine cream; Group B received one-week pulse therapy with capsule itraconazole once every four-week for three pulses. The response was assessed by Onychomycosis Severity Index, a validated onychomycosis assessment scale, at baseline and at six months. Results Group A had 50 patients with a total of 98 nails. Clinical improvement was seen in 83/98 (84.7%) nails. The average reduction in Onychomycosis Severity Index was 8.65 (P < 0.05). Group B had 50 patients with a total of 136 nails. Clinical improvement was seen in 104/136 (76.5%) nails. The average reduction in Onychomycosis Severity Index was 7.37 (P < 0.05). Both groups showed statistically significant improvement measured by 'Reduction in Onychomycosis Severity Index' at six months; however, there was no significant difference between the two arms. Limitations The main limitations of the study are the small sample size and lack of long-term follow-up to assess recurrence of infection. Conclusion Fractional CO2 laser with 1% terbinafine cream is an effective and safe method for inducing nail clearance in onychomycosis and has efficacy similar to itraconazole pulse therapy.


Asunto(s)
Láseres de Gas , Onicomicosis , Humanos , Terbinafina/uso terapéutico , Itraconazol , Onicomicosis/diagnóstico , Onicomicosis/tratamiento farmacológico , Antifúngicos , Estudios Prospectivos , Láseres de Gas/uso terapéutico , Naftalenos , Resultado del Tratamiento , India
6.
Indian J Dermatol Venereol Leprol ; 88(4): 494-499, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-34877858

RESUMEN

Background Although topical amphotericin B cream is effective for the treatment of nondermatophyte mold onychomycosis in vitro, studies of its effectiveness and safety in vivo are limited. Objectives We studied the effectiveness and safety of topical 0.3% amphotericin B in 30% dimethyl sulfoxide cream (amphotericin B cream) in nondermatophyte mold onychomycosis using the vehicle cream 30% dimethyl sulfoxide cream as control. Methods This randomized controlled study was conducted between January 2019 and November 2020. Patients diagnosed with nondermatophyte mold onychomycosis were randomly divided into two groups of ten patients each: one treated with amphotericin B cream and the other with the vehicle cream. Clinical and mycological cure as well as safety were evaluated. Results Ten patients each treated with amphotericin B cream and the vehicle cream were included in the study, but only nine patients in the vehicle cream group were available for follow up. All the 19 evaluable patients had distal lateral subungual onychomycosis and the great toenails were affected in 18 (94.7%) of these. Mycological cure was achieved in 8 (80%) patients treated with amphotericin B cream and in 4 (44.4%) patients using the control (vehicle) cream. Clinical cure was achieved in 7 (70%) patients treated with amphotericin B cream, but only in 2 (22.2%) patients on the control cream. No adverse events were observed. Limitations The small sample size and the fact that PCR fungal identification that provides accurate identification of fungal species was not performed are limitations of our study. Conclusion Topical amphotericin B cream was both very effective and safe in the treatment nondermatophyte mold onychomycosis. The control (vehicle) cream containing 30% dimethyl sulfoxide also demonstrated some antifungal activity.


Asunto(s)
Dermatosis del Pie , Onicomicosis , Administración Tópica , Anfotericina B/uso terapéutico , Antifúngicos , Dimetilsulfóxido/uso terapéutico , Dermatosis del Pie/tratamiento farmacológico , Humanos , Onicomicosis/diagnóstico , Onicomicosis/tratamiento farmacológico , Proyectos Piloto , Resultado del Tratamiento
8.
Indian J Dermatol Venereol Leprol ; 86(4): 341-349, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32415047

RESUMEN

BACKGROUND: Diagnosis of onychomycosis involves direct microscopic examination with potassium hydroxide, culture or histopathology with periodic acid-Schiff staining. Nail dermoscopy (onychoscopy) is a noninvasive, rapid and easily available diagnostic tool though its utility in onychomycosis remains unexplored. OBJECTIVE: To describe the various onychoscopic patterns and compare its percentage positivity with that of standard potassium hydroxide examination, culture and histopathology in patients with a clinical diagnosis of onychomycosis. METHODS: The study recruited 100 patients with a presumptive clinical diagnosis of onychomycosis. A detailed history, physical examination including that of nails and clinical photography was followed by onychoscopy with DermLite DL3. The nail clippings were sent for direct microscopic examination with potassium hydroxide, mycological culture and histopathology with periodic acid-Schiff stain. The patient was said to have onychomycosis if at least one of the three tests was positive. RESULTS: Onychomycosis was confirmed by potassium hydroxide and/or culture and/or histopathology in 88 patients. Onychoscopic features were identified and their association with different clinical variants of onychomycosis was attempted. Percentage positivity for diagnosing onychomycosis in decreasing order was: direct microscopic examination with potassium hydroxide followed by spiked pattern, subungual hyperkeratosis, distal irregular termination on onychoscopy, histopathology, mycological culture and ruins aspect again observed on onychoscopy. LIMITATIONS: Small sample size. CONCLUSIONS: Many onychoscopic features are highly specific for different variants of onychomycosis so onychoscopy may serve as an important and quick adjunct to diagnose onychomycosis until other time-consuming investigations, such as culture and periodic acid-Schiff become available. Studies on a larger population will help arrive at a logistic conclusion.


Asunto(s)
Dermoscopía , Onicomicosis/diagnóstico por imagen , Adulto , Recuento de Colonia Microbiana , Estudios Transversales , Humanos , Hidróxidos , Microscopía , Onicomicosis/patología , Compuestos de Potasio , Valor Predictivo de las Pruebas
16.
Eur J Pharm Biopharm ; 102: 32-40, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-26924329

RESUMEN

We hypothesised that Hansen Solubility Parameters (HSPs) can be used to predict drug-nail affinities. Our aims were to: (i) determine the HSPs (δD, δP, δH) of the nail plate, the hoof membrane (a model for the nail plate), and of the drugs terbinafine HCl, amorolfine HCl, ciclopirox olamine and efinaconazole, by measuring their swelling/solubility in organic liquids, (ii) predict nail-drug interactions by comparing drug and nail HSPs, and (iii) evaluate the accuracy of these predictions using literature reports of experimentally-determined affinities of these drugs for keratin, the main constituent of the nail plate and hoof. Many solvents caused no change in the mass of nail plates, a few solvents deswelled the nail, while others swelled the nail to varying extents. Fingernail and toenail HSPs were almost the same, while hoof HSPs were similar, except for a slightly lower δP. High nail-terbinafine HCl, nail-amorolfine HCl and nail-ciclopirox olamine affinities, and low nail-efinaconazole affinities were then predicted, and found to accurately match experimental reports of these drugs' affinities to keratin. We therefore propose that drug and nail Hansen Solubility Parameters may be used to predict drug-nail interactions, and that these results can assist in the design of drugs for the treatment of nail diseases, such as onychomycosis and psoriasis. To our knowledge, this is the first report of the application of HSPs in ungual research.


Asunto(s)
Uñas/efectos de los fármacos , Preparaciones Farmacéuticas/administración & dosificación , Preparaciones Farmacéuticas/metabolismo , Adolescente , Adulto , Antifúngicos/administración & dosificación , Ciclopirox , Interacciones Farmacológicas , Femenino , Humanos , Queratinas/metabolismo , Masculino , Persona de Mediana Edad , Morfolinas/farmacología , Enfermedades de la Uña/tratamiento farmacológico , Enfermedades de la Uña/metabolismo , Enfermedades de la Uña/microbiología , Uñas/metabolismo , Naftalenos/farmacología , Onicomicosis/tratamiento farmacológico , Onicomicosis/metabolismo , Piridonas/farmacología , Solubilidad , Terbinafina , Triazoles/farmacología , Adulto Joven
19.
Artículo en Inglés | MEDLINE | ID: mdl-26087080

RESUMEN

INTRODUCTION: Dermatophytes are the most frequently implicated agents in toenail onychomycosis and oral terbinafine has shown the best cure rates in this condition. The pharmacokinetics of terbinafine favors its efficacy in pulse dosing. OBJECTIVES: To compare the efficacy of terbinafine in continuous and pulse dosing schedules in the treatment of toenail dermatophytosis. METHODS: Seventy-six patients of potassium hydroxide (KOH) and culture positive dermatophyte toenail onychomycosis were randomly allocated to two treatment groups receiving either continuous terbinafine 250 mg daily for 12 weeks or 3 pulses of terbinafine (each of 500 mg daily for a week) repeated every 4 weeks. Patients were followed up at 4, 8 and 12 weeks during treatment and post-treatment at 24 weeks. At each visit, a KOH mount and culture were performed. In each patient, improvement in a target nail was assessed using a clinical score; total scores for all nails and global assessments by physician and patient were also recorded. Mycological, clinical and complete cure rates, clinical effectivity and treatment failure rates were then compared. RESULTS: The declines in target nail and total scores from baseline were significant at each follow-up visit in both the treatment groups. However, the inter-group difference was statistically insignificant. The same was true for global assessment indices, clinical effectivity as well as clinical, mycological, and complete cure rates. LIMITATIONS: The short follow-up in our study may have led to lower cure rates being recorded. CONCLUSION: Terbinafine in pulse dosing is as effective as continuous dosing in the treatment of dermatophyte toenail onychomycosis.


Asunto(s)
Antifúngicos/administración & dosificación , Dermatosis del Pie/tratamiento farmacológico , Naftalenos/administración & dosificación , Onicomicosis/tratamiento farmacológico , Adulto , Método Doble Ciego , Esquema de Medicación , Femenino , Dermatosis del Pie/microbiología , Humanos , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Terbinafina , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA